J Menopausal Med.  2016 Aug;22(2):65-70. 10.6118/jmm.2016.22.2.65.

Cervical Cancer Screening after Perimenopause: How Is Human Papillomavirus Test Performed?

• Chung SH

• KMID: 2365460
• DOI: http://doi.org/10.6118/jmm.2016.22.2.65

Abstract

Cervical cancer is the third most prevalent cancer in women around the world. Recently in Korea, the incidence of cervical cancer has decreased, but in all stages of cervical intraepithelial neoplasia (CIN), CIN has shown a 91% increase from 1999 to 2008. Persistent human papillomavirus (HPV) infection has been found to be the main cause of cervical cancer. HPV types 16 and 18 have been found in 70% of cervical cancer patients around the world. Cervical cancer screening such as cytology has limitations in terms of sensitivity and specificity. A discussion about the need for the HPV test is becoming active in order to compensate for the limitation of cytology. After the role of HPV in cervical cancer was identified, the importance of HPV detection test as a screening was emphasized. Several tests have been developed and each test has its own advantages and disadvantages, and new test method to overcome the disadvantages is still being developed. Today's guidelines and tests are those you would choose from among the large number of cervical cancer screening guidelines and tests, based on the consideration that the selected guidelines and the test are effective.

Keyword

Early detection of cancer; Human papilloma virus; Perimenopause; Uterine cervical neoplasms

MeSH Terms

Cervical Intraepithelial Neoplasia
Early Detection of Cancer
Female
Humans*
Incidence
Korea
Mass Screening*
Methods
Papillomaviridae
Perimenopause*
Sensitivity and Specificity
Uterine Cervical Neoplasms*

Reference

1. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12:663–672.

2. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; 22:2675–2686.

3. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014; 46:109–123.

4. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121:621–632.

5. Park J, Kim TH, Lee HH, Lee WS, Chung SH. Prevalence of human papilloma virus infection in perimenopausal women in Bucheon province. J Korean Soc Menopause. 2011; 17:155–159.

6. Kim TH, Lee HH. Media effect--Letter to the editor about the manuscript titled: increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet. 2014; 289:473–474.

7. Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015; 65:30–54.

8. Satsuka A, Sakai H. Life cycle of HPV governed by the differentiation program of epithelial cell. Uirusu. 2008; 58:165–172.

9. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013; 445:232–243.

10. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012; 131:2349–2359.

11. Carozzi F, Ronco G, Gillio-Tos A, De Marco L, Del Mistro A, Girlando S, et al. Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer. 2012; 48:1633–1637.

12. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 2011; 19:33–39.

13. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011; 136:578–586.

14. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136:189–197.

15. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156:880–891. w312

16. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012; 206:46.e1–46.e11.

17. Austin RM, Onisko A. Increased cervical cancer risk associated with extended screening intervals after negative human papillomavirus test results: Bayesian risk estimates using the Pittsburgh cervical cancer screening model. J Am Soc Cytopathol. 2016; 5:9–14.

18. Baleriola C, Millar D, Melki J, Coulston N, Altman P, Rismanto N, et al. Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections. J Clin Virol. 2008; 42:22–26.

19. Davey DD, Goulart R, Nayar R. Update on HPV test utilization. Am J Clin Pathol. 2014; 141:759.

20. Davey DD, Goulart R, Nayar R. 2013 statement on human papillomavirus DNA test utilization. Am J Clin Pathol. 2014; 141:459–461.

21. Shepherd LJ, Bryson SC. Human papillomavirus--lessons from history and challenges for the future. J Obstet Gynaecol Can. 2008; 30:1025–1033.

22. Choi SD, Kim TH, Bae DH. Cervical intraepithelial neoplasia based on array comparative genomic hybridization. Eur J Gynaecol Oncol. 2014; 35:270–273.

23. Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012; 125:343–345.

24. Gyllensten U, Lindell M, Gustafsson I, Wilander E. HPV test shows low sensitivity of Pap screen in older women. Lancet Oncol. 2010; 11:509–510.

25. Smith EM, Johnson SR, Ritchie JM, Feddersen D, Wang D, Turek LP, et al. Persistent HPV infection in postmenopausal age women. Int J Gynaecol Obstet. 2004; 87:131–137.

26. Lee JK, Hong JH, Kang S, Kim DY, Kim BG, Kim SH, et al. Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol. 2013; 24:186–203.